Kypha
St. Louis, US · Founded 2009 · Delaware corporation · 11 employees on LinkedIn · 3 known investors
Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.
Founders & leadership
Kypha was founded in 2009 by Chad M. Stiening.
CM
Chad M. StieningFounder
NS
Nick StatenExecutive
TS
T. Scott GloverExecutive
PK
Paul K. OlsonExecutive
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$14.3M disclosed across 6 rounds · 2011–2022
▶$5.2MraisedMay 2022 · 13 investors · Other Health CareRule 506(b)
▶$5.2MraisedMay 2022 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Chad StieningExecutive Officer, Director
- Gerhard BetteDirector
- Dennert WareDirector
- James MerselisDirector
- Peter ReineckeDirector
- Offering amount
- $17M
- Amount sold
- $5.2M
- Minimum investment
- $1
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$950KraisedJul 2018 · 1 investors · Other Health CareRule 506(b)
▶$950KraisedJul 2018 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter ReineckeDirector
- James MerselisDirector
- Jonathan SackierDirector
- Chad StieningExecutive Officer, Director
- Offering amount
- $950K
- Amount sold
- $950K
- Minimum investment
- $1
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMay 2018 · 13 investors · Other Health CareRule 506(b)
▶$5.5MraisedMay 2018 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James MerselisDirector
- Jonathan SackierDirector
- Chad StieningExecutive Officer, Director
- Peter ReineckeDirector
- Offering amount
- $7.9M
- Amount sold
- $5.5M
- Minimum investment
- $1
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedNov 2015 · 3 investors · Other Health CareRule 506(b)
▶$2.1MraisedNov 2015 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nick StatenExecutive Officer
- T. Scott GloverExecutive Officer
- James D. MarselisDirector
- Peter ReineckeDirector
- Jonathan SackierDirector
- David SmollerDirector
- Chad StieningDirector
- Offering amount
- $3.2M
- Amount sold
- $2.1M
- Minimum investment
- $15K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$398.4KraisedJan 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$398.4KraisedJan 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David SmollerDirector
- Chad StieningExecutive Officer, Director
- Peter ReineckeDirector
- Peter A. TakesExecutive Officer
- Sultan MeghjiDirector
- Nick StatenExecutive Officer
- Paul OlsonExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $398.4K
- Minimum investment
- $1
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
▶$206KraisedJan 2012 · 10 investors · BiotechnologyRule 506(b)
▶$206KraisedJan 2012 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chad M. StieningExecutive Officer, Director
- R. Charles MoyerDirector
- Paul K. OlsonExecutive Officer, Director
- T. Vernon FosterDirector
- Offering amount
- $500K
- Amount sold
- $206K
- Minimum investment
- $8K
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Qpex Biopharma3 shared keywordsQpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria. The company operates R&D laboratories in San Diego, California, working alongside Shionogi's research labs in Japan.
Companies competing with Kypha for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $218.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $273.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Kypha do?
- Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.
- Who founded Kypha?
- Kypha was founded by Chad M. Stiening in 2009.
- Who are Kypha's investors?
- Kypha's investors include BioGenerator Ventures, Missouri Technology Corporation, Serra Ventures.
- How much funding has Kypha raised?
- Kypha has disclosed $14.3M raised across 6 rounds.
- Where is Kypha headquartered?
- Kypha is headquartered in St. Louis, US.